Autor: |
Frølund, L, Durham, S R, Calderon, M, Emminger, W, Dahl, R, Andersen, Jens S., Rask, P. |
Jazyk: |
angličtina |
Rok vydání: |
2009 |
Předmět: |
|
Zdroj: |
Frølund, L, Durham, S R, Calderon, M, Emminger, W, Dahl, R, Andersen, J S & Rask, P 2009, ' Sustained effect of SQ-standardized grass allergy immunotherapy tablet on rhinoconjunctivitis quality of life ', Allergy: European Journal of Allergy and Clinical Immunology . https://doi.org/10.1111/j.1398-9995.2009.02238.x |
Popis: |
Udgivelsesdato: 2009-Nov-2 Background: The prevalence of allergic rhinoconjunctivitis has increased significantly over the past decades with grass pollen being a common trigger. The impact of allergy on patient's quality of life is substantial. Aim: To investigate the sustained effect on quality of life during the grass pollen season 1 year after 3 years of treatment with the SQ-standardized grass allergy immunotherapy tablet (AIT), Grazax((R)) (Phleum pratense 75,000 SQ-T/2800 BAU; ALK, Denmark). Methods: The trial was a randomized, parallel-group, double-blind, placebo-controlled trial in adult subjects with a history of moderate-severe grass pollen induced rhinoconjunctivitis inadequately controlled by symptomatic medications. Subjects received 3 years of grass AIT (n = 157) or placebo (n = 126), followed by 1 year of follow-up. Quality of life assessments were based on the standardized rhinoconjunctivitis quality of life questionnaire (RQLQ(S)); completed weekly during the entire grass pollen season. Results: During follow-up, the overall RQLQ(S) score for the entire grass pollen season was significantly improved in the active group (relative difference to placebo: 23%, P = 0.004). The improvement was higher during the peak pollen season (28%, P = 0.001). The treatment effect of grass AIT during the follow-up year and the previous three treatment years was similar. Improvements were found in all seven RQLQ(S) domains. The RQLQ(S) as a function of the weekly average pollen counts showed a clear separation between the treatment groups (P < 0.001). Conclusion: In subjects inadequately controlled by symptomatic medications, grass AIT provided sustained and clinically relevant improvements in rhinoconjunctivitis quality of life compared to placebo. The effect increased with increasing grass pollen exposure. |
Databáze: |
OpenAIRE |
Externí odkaz: |
|